The U.K.'s largest charity has already begun to pour some serious pounds into biotech startups. The Wellcome Trust has organized its efforts under a new venture unit called Syncona to back early-stage outfits in biotech and other healthcare sectors with an initial £200 million ($325 million) fund.
London-based Cell Medica is coming to America. The cell therapy developer says it has pieced together a $26.5 million round to finance new operations in Texas to work on a cancer immunotherapy program.
Edmond de Rothschild Investment Partners, a high-profile venture player in the European life sciences scene, has braved a tough financial environment and rounded up a bit more than $152 million for its fourth biotech fund.
Fresh on the heels of the news of a disappointing quarter for biotech investing in the U.S., Dow Jones VentureSource has done the math for Europe and come up with an equally dispiriting set of stats.
U.K. officials are preparing for the imminent launch of a $286 million fund designed to revive the country's biotech industry.
Wellcome Trust no longer wants to pay for medical research that ends up guarded behind a pay wall.
The analysts at Burrill & Co. took out their calculators and concluded that $2.6 billion in new venture funds for translation and early-stage work materialized in the U.S. and Europe in the last two months.
The U.K's wealthiest charity has blueprinted big plans to back fledgling therapeutics and diagnostics companies with a brand new £200 million ($317 million) fund.
A team of university researchers in the U.K. are working on an efficient formula for creating mass stocks of synthetic blood from stem cells. And they say may be just a couple of years from beginning
The largest-ever clinical trial in patients suffering from severe malaria--funded by the Wellcome Trust and published in The Lancet--is recommending that a 300-year-old treatment for the disease that